Skip to main content
. 2020 Feb 15;12(2):478–492.

Figure 4.

Figure 4

FASSs increased the expression and phosphorylation of AKT, ERK1/2, and p38 in a dose-dependent manner. Western blot was performed to determine the expression of (A) AKT1 and p-AKT1, (B) ERK1/2 and p-ERK1/2, and (C) p38 and p-p38 in the control (0) and HUVECs treated with different concentrations of FASSs as indicated. Inhibitors AZD5363 (AKT inhibitor), SCH772984 (ERK inhibitor), and SB203580 (p38 MAPK inhibitor) were also used to identify the pathways induced by FASSs. (D) In the scratch and Transwell assays, simultaneous application of these inhibitors completely abolished the effects of FASSs on the activation of these molecules. *P<0.05, **P<0.01, compared with control. #P<0.05, compared with the FASS group.